Skip to main content

Is The German SPD Parliamentary Group Against Legalization?

The ongoing legalization saga in Germany often feels like something out of a soap opera. Since the summer of 2021, when the current governing coalition was elected in Germany, the push for legalization has experienced several ups and downs.

Between the summer of 2021 and October 2022, cannabis observers inside Germany and around the world watched with collectively held breath waiting for a legalization measure to be formally introduced. What was touted after the 2021 federal election was a robust, nationwide sales system similar to what is in place in Canada.

Several leaks surfaced in news coverage regarding what the legalization measure would include, along with various reactions from German lawmakers every time headlines were made. Many lawmakers expressed frustration with the process during that period.

In October 2021, the world finally got its first glimpse into a legalization measure largely championed by Germany’s Minister of Health Dr. Karl Lauterbach. Unfortunately, the measure that was described in a press conference held by Minister Lauterbach at the time was a rolled-back version of what many advocates had hoped for.

Minister Lauterbach described his measure as being multi-phased, with the first phase permitting personal cannabis cultivation, possession, and consumption, along with permitting noncommercial cannabis clubs to operate. It would also remove cannabis from the nation’s narcotics law.

A second phase, which would need to come later via a separate measure, would permit the launch of regional adult-use cannabis commerce pilot programs. Yet, before any of that was to be formally set in motion, Minister Lauterbach made it clear that he would first seek European Union approval of his plan before introducing it.

Minister Lauterbach eventually introduced his measure in 2023, with the measure receiving approval by Germany’s Federal Cabinet earlier this year. The measure also passed the Bundesrat, only to experience some turbulence in the Bundestag. Earlier this month the measure appeared to be dead for the year, then it was announced that a vote was expected, just for the vote to never actually happen.

Various media accounts surfaced this month blaming members of the SPD parliamentary group for the measure failing to receive a vote. Bundestag member Dr. Rolf Mützenich (SPD) was recently asked, “Dear Mr. Mützenich, are you worried about the citizens’ severe loss of trust in the SPD due to the repeated postponement of the vote on the CanG or does it not matter to you?”

Dr. Mützenich replied with, “The SPD parliamentary group continues to support the bill to decriminalize cannabis. It is regrettable that other reports spread a false impression – perhaps deliberately. The SPD has long campaigned for a liberal drug policy and failed to do so due to the Union under Chancellor Merkel.”

“We are now committed to ensuring that the law will, above all, take health protection into account; final discussions are still being held on this matter. The law is scheduled to be passed at the beginning of next year and, we intend, to come into force in April 2024 as planned.” Dr. Mützenich also stated.

The timeline offered up by Dr. Mützenich is in line with previous statements made this month by members of the Bundestag. Whether or not the timeline proves to be accurate is something that we will all have to wait and see.

As far as whether the SPD parliamentary group is for or against legalization in Germany, it appears that at the very least there are mixed opinions within the political party, but hopefully there is more support for policy modernization than there is for continued status quo-maintaining foot-dragging.

Fewer Youth Say Cannabis Is “Easy” To Access Post-Canada Legalization

A popular talking point among cannabis opponents leading up to cannabis policy reform, including medical cannabis policy reform, is that reform will ‘increase youth access to cannabis.’ It is a talking point that opponents seem to always hurl into the public sphere when policy reform is being considered by lawmakers or voters.

What cannabis opponents fail to recognize is that regulating cannabis involves checking government-issued identification to ensure that the person is permitted to acquire cannabis. A regulated industry also involves compliance checks and audits, all of which make it much harder for youth to access cannabis. None of that is true of the unregulated market.

According to a recent survey conducted in Canada, where cannabis was legalized for adult use in 2018, fewer young people are reporting that it is “easy” to access cannabis. Below is more information about it via a news release from NORML:

Waterloo, Canada: The percentage of young people who say that it is “easy” for them to acquire cannabis has decreased significantly since Canada legalized the adult-use marijuana market, according to data published in the journal Archives of Public Health.

Canadian researchers assessed young people’s perceptions surrounding the availability of cannabis products. They determined that the percentage of underage youth reporting that cannabis was easy to access decreased by 27 percent from 2018 – the year Canada legalized cannabis markets nationwide – to 2020. Self-reported marijuana consumption by young people also decreased during this period.

The study’s authors concluded: “While there has been a growing number of studies focused on examining changes in cannabis use among Canadian youth since the onset of the Cannabis Act, and more recently since the onset of the COVID-19 pandemic, there appears to be a paucity of research dedicated to examining changes in youth perceptions of cannabis availability over the same period of time. In response, this study provides unique and novel evidence of how youth perceptions of cannabis access have changed since the onset of the Cannabis Act. … Our data suggest that in our large samples of youth, perceptions of cannabis access as being easy has declined in prevalence since legalization and through the early and ongoing pandemic response period.”

Data from the United States has similarly failed to identify any significant uptick in youth marijuana use following the adoption of state-level legalization. According to a May 2023 report from the US Centers for Disease Control and Prevention, the percentage of high schoolers who ever tried marijuana fell 30 percent between 2011 and 2021 – during which time nearly half of all US states legalized cannabis. The percentage of students who self-identified as current marijuana consumers decreased by a similar percentage during the same period.

Full text of the study, “Youth perceptions of difficulty accessing cannabis following cannabis legalization and during the early and ongoing stages of the COVID-19 pandemic: Repeat cross-sectional and longitudinal data from the COMPASS study,” appears in Archives of Public HealthAdditional information on cannabis use trends among young people is available from the NORML Fact Sheet, ‘Marijuana Regulation and Teen Use Rates.’

SDP Leadership: German Legalization Vote Expected In Early 2024

As 2023 continues to wind down, cannabis advocates and policymakers in Germany are turning their focus to 2024 with hopes that it will prove to be the year that a long-awaited national adult-use cannabis legalization measure is finally passed and implemented in Europe’s largest economy.

The parliamentary group leader of Germany’s Social Democratic Party recently indicated that a legalization vote “will come at the beginning of 2024.” Rolf Mützenich, chairman of the SPD parliamentary group, made the statement in a recent interview with Rheinische Post.

Germany’s ongoing cannabis policy modernization saga has experienced a lot of highs and lows, even as recently as this month. At the start of December, it appeared that a long-awaited legalization vote in the Bundestag would not happen until 2024.

Then, in a surprise turnaround, it was announced that the governing coalition reached an agreement to update certain provisions of the measure and that a vote would take place before the end of the year.  That expected vote was then unceremoniously pulled back, and now we are essentially back to where we started at the beginning of December.

“It also remains unclear whether the SPD parliamentary group leadership has a problem with the content of the law or whether the timing of its adoption just before Christmas seems inappropriate to them in times of budget crisis. And the SPD press spokeswoman’s “confidence” or not: it doesn’t seem impossible that the law might even be stopped completely “on the home stretch.” Legal Tribune Online stated in its reporting at the time.

In his recent wide-ranging interview with Rheinische Post, chairman of the SPD parliamentary group Rolf Mützenich stated (translated from German to English), “We are taking a close look at the concerns. But we have agreed on this project in the coalition and it will come at the beginning of 2024. I assume so.”

Fellow Social Democratic Party member Burkhard Blienert, who initially introduced the cannabis legalization measure being considered by Bundestag members and continues to lead ongoing talks with the European Union, recently urged his fellow lawmakers to take action:

At this point, no one can count their metaphorical German legalization eggs until they actually hatch. As we have seen over the course of the last two years, the political process can be full of delays and setbacks.

For the sake of compassion, logic, and good stewardship of public resources lawmakers in Germany need to get the ball rolling as early as possible in 2024. What is currently being proposed is already found elsewhere in Europe at this point, albeit in smaller nations.

Malta and Luxembourg already permit adult-use cultivation and possession. Additionally, Malta has now licensed five entities to operate noncommercial cannabis clubs. Limited adult-use cannabis trials are underway in both Switzerland and the Netherlands. With that in mind, Germany now has some catching up to do, and hopefully that happens sooner rather than later.

Guernsey Cannabis Prescriptions Top 13,000 In Last Year

Guernsey, a self-governing British Crown dependency island in the English Channel near the French coast, only has a population of roughly 65,000 people. Yet, three private clinics on the island have reportedly issued over 13,000 medical cannabis prescriptions over the course of the last year.

Medical cannabis reform was first implemented in Guernsey in 2019, with the British Crown dependency issuing its first medical cannabis cultivation license in November 2021. Momentum for adult-use reform picked up in recent years, however, actual passage and implementation of an adult-use cannabis measure seems unlikely for the foreseeable future.

Lawmakers in Guernsey agreed in 2022 to explore the idea of adult-use cannabis reform. Unfortunately, all laws passed by Guernsey’s government must also be approved by the United Kingdom’s Privy Council – a concept known as ‘royal assent.’

“One of the hurdles we’ve encountered as we have looked more deeply in cannabis legalisation is getting royal assent in the UK [passed by the King’s Privy Council, which, at the moment, appears very unlikely.” stated Policy & Resources Committee member Deputy Bob Murray earlier this year.

A survey of domestic lawmakers in Guernsey back in the summer of 2022 found that over half of them supported reviewing the nation’s cannabis policies, with 40% of survey respondents indicating that they supported rescheduling cannabis.

For now, Guernsey’s emerging medical cannabis industry will continue to serve patients via the prescription process. If local lawmakers and industry members have their way, Guernsey’s industry will increase in size and scope in the coming years, and serve patients in other jurisdictions.

The stated goal coming out of Guernsey is for companies to be able to import raw cannabis from other jurisdictions, make them into various products, and then export those finished products to large European markets such as Germany.

However, for that to happen a “massive investment” needs to be made into the industry according to Deputy Marc Leadbeater, and investors seem hesitant.

“The problem is a lot of the previous investors in medicinal cannabis are wary about investing in that area at the moment due to developments with cannabis legislation across the globe.” Deputy Leadbeater stated according to reporting by the BBC.

Cannabis Trials Begin In The Netherlands After Long Delay

Limited adult-use cannabis commerce trials finally launched this week in the Netherlands after several delays. Cannabis trials, which permit consumers, growers, and retailers to participate in legal cannabis commerce for research purposes, were first proposed in the Netherlands in 2017 as part of a governing coalition agreement.

“The aim of the experiment is to ascertain whether or not it is possible to regulate a quality-controlled supply of cannabis to coffee shops and to study the effects of a regulated supply chain on crime, safety, public nuisance and public health. In order to allow the experiment to take place, special legislation must be adopted.” the Netherlands’ government stated at the time.

The push to launch cannabis trials in the Netherlands has experienced a series of setbacks. Back in September 2019, ten municipalities were selected for participation in the trials, although legislation was still needed to allow the trials to proceed.

On January 22, 2019, the nation’s House of Representatives adopted a controlled cannabis supply chain experiment measure, followed by passage in the Senate on November 12, 2019. That afforded some of the estimated 570 cannabis-selling coffee shops in the country a path to participate in the eventual trials.

The initial timeline to launch the trials was 2021, however, that did not happen. The same was true for 2022, with the year coming and going and the Netherlands seeming to be no closer to achieving the full implementation of initial cannabis trials. The delays were reportedly due to a lack of legal supply.

At one point in 2023, it appeared that the whole year would be lost to more delays, with the nation’s Health Minister Ernst Kuipers indicating that they did not want to roll out the trials in phases. Fortunately, the trials did launch this week in Breda and Tilburg.

Cannabis trials are not unique to the Netherlands. Multiple cannabis trials are already underway in Switzerland, such as in cities like Zurich and Basel, with more expected to be launched in the next calendar year.

The public policy concept of cannabis trials is a key component of the legalization model being pursued in Germany. Germany’s Commissioner for Addiction and Drug Issues Burkhard Blienert recently traveled to The Netherlands to discuss the concept:

Cannabis trials are expected to launch in other cities in the Netherlands, although it is still unclear when that will happen exactly. Arnhem, Almere, Groningen, Heerlen, Hellevoetsluis, Maastricht, Nijmegen, and Zaanstad are other municipalities in the Netherlands selected for cannabis trials.

Malta Approves More Noncommercial Cannabis Clubs

Malta became the first European nation to pass an adult-use cannabis legalization measure back in 2021. The passage of a national legalization measure in Malta made the country the third nation on earth to do so, following Uruguay and Canada.

Unlike Uruguay and Canada, adult-use sales in Malta are limited to noncommercial cannabis clubs. Dispensaries and adult-use sales at pharmacies are still prohibited in Malta, in addition to other forms of commerce.

Back in October Malta approved its first round of licenses for noncommercial cannabis clubs, and earlier this month it approved another round, with three more entities receiving approval. Per Cannabis Health News:

Malta’s Responsible Cannabis Use Authority (CURA) has issued three new licences to Cannabis Harm Reduction Associations (CHRAs).

This brings the total to five clubs which have now received approval, with Sprawt, Northern Lights and NEGE joining KDD Society and Ta’ Zelli which were licensed in early November.

Regulations state that only associations listed on the CURA website can cultivate and distribute cannabis to their members. Membership is limited to residents of Malta over the age of 18 and a copy of their identity card must be provided to the association as proof of age and address.

Unfortunately, the European Union does not permit its members to legalize national adult-use sales. Rather, all policy modernization has to be medical and/or research in nature, which is why Malta was permitted to proceed with licensing noncommercial cannabis clubs.

Such clubs are geared towards reducing the public health impact related to humans consuming unregulated products.

Another public policy experiment that is found in Europe involves the permitting of adult-use cannabis commerce pilot programs. As of right now, Malta does not have plans to launch such programs. Limited local pilot programs are one form of commerce that the European Union permits since they are geared toward research.

Push For Legalization Continues In Costa Rica

Multiple countries on different continents are making meaningful pushes to modernize their cannabis policies in ways that would permit adults to cultivate, consume, and/or sell cannabis for recreational purposes.

One of those countries is Costa Rica, where lawmakers are divided over a recent effort to pass an adult-use cannabis legalization measure. This month the nation’s president once again called for adult-use cannabis legalization, and the call was received with mixed reactions. Per excerpts from Tico Times:

Several deputies across parties echoed Chaves’ perspective. Manuel Morales, President of the Environment Commission that oversees the stalled legalization bill, agrees the goal is regulating existing demand rather than promoting more usage.

However, some legislators remain fiercely opposed, especially from the opposition National Liberation Party (PLN). Deputy Dinorah Barquero alleged the bill lacks sufficient study of potential public health impacts from increased cannabis use. Meanwhile, fellow PLN member Gilbert Jiménez labeled Chaves’ legalization push as “inopportune” given the scale of Costa Rica’s security challenges with homicides and criminal groups.

Costa Rica’s Executive Branch previously introduced a cannabis legalization measure that would be later voted down by the nation’s Permanent Special Environment Commission in a 5-3 vote back in August. A major focus of the measure was to boost the nation’s tourism industry and to make Costa Rica a top global cannabis tourism destination.

In President Chaves’ recent call to renew the push to legalize cannabis for adult use in his country, he placed a heavy emphasis on modernizing the nation’s policies to help combat drug cartels and organized crime.

Costa Rica is reportedly experiencing an interesting phenomenon, with cannabis allegedly being smuggled into the country at an increasing rate. If so, Costa Rica would be wise to follow in Canada’s footsteps. Canada legalized cannabis in 2018 and consumers have largely transitioned their purchases to the regulated industry instead of buying from unregulated sources.

Most Surveyed Swiss Psychiatrists Favor Regulating Cannabis

According to a team of researchers associated with the University of Bern in Switzerland, medical cannabis is “a growing issue” in psychiatry, with more patients asking about it now that cannabis policies are being modernized in Switzerland and beyond.

The researchers note that Switzerland amended its laws in 2021 to permit adult-use cannabis commerce pilot programs to be conducted at the municipal level and that there is a rising need to examine attitudes towards cannabis, including within the mental health professional community. The researchers surveyed psychiatrists in Switzerland in a recent study.

“From December 2021 to February 2022, we conducted an online survey of psychiatrists in Switzerland. The survey comprised questions on attitudes towards regulative models for CNMU and towards prescribing CMU for mental disorders.” the researchers stated about their survey methodology.

“We contacted 2010 psychiatrists in Switzerland. A total of 274 (14%) participated in the survey.” the researchers also stated.

“Sixty-four percent agreed to a regulated legalization of CNMU, and 89% would welcome pilot trials in Switzerland assessing models for regulating CNMU with those from a French-speaking region being more skeptical.” the researchers stated about their findings.

Forty-nine percent of psychiatrists agree that CMU might have a therapeutic effect in mental disorders, but 50% agree that there is not enough scientific evidence yet. Participants working in an inpatient setting or in a French-speaking region as well as those with a longer duration of practice were more skeptical on CMU for mental health.” the researchers also stated about their study’s findings.

“Most surveyed Swiss psychiatrists favor the regulation of CNMU and the conduct of pilot trials. Despite little evidence and potential negative consequences, many participating Swiss psychiatrists agreed that cannabis could be efficacious in the treatment of some mental disorders advocating for more research in this topic.” the researchers concluded.

German Commissioner Visits The Netherlands To Learn About Cannabis Trials

The European continent is home to a handful of interesting local cannabis public policy experiments often referred to as cannabis pilot trials or programs. The trials are designed, in theory, to collect consumer and commerce data at a local level to help national policymakers when they are crafting broader laws, rules, and regulations.

Switzerland has trials already in operation in multiple cities, each with its limits on the number of participants that can take part in the public policy experiment. The trials in Switzerland range in size from hundreds of consumers up to thousands, with each consumer being able to make legal purchases from regulated outlets that are also participating in the programs.

The adult-use legalization measure being considered in Germany also incorporates the concept of local cannabis commerce trials. Germany’s Commissioner for Addiction and Drug Issues Burkhard Blienert traveled to The Netherlands recently to discuss the concept:

Cannabis trials are not a part of adult-use legalization models in the Western Hemisphere. In both Uruguay and Canada, the first two nations to pass national adult-use legalization measures, cannabis sales are permitted nationwide. It is worth noting that Uruguay limits legal purchases to residents only.

The only other two nations to pass adult-use legalization measures at a national level are Malta and Luxembourg, and in the case of Luxembourg, the nation’s legalization model is very restrictive. Sales of any kind are still prohibited in Luxembourg.

In Malta, personal cultivation, possession, and consumption are all legal for adults, as well as permitted purchases via the nation’s growing list of noncommercial cannabis clubs. Malta has no current plans to expand its legalization model.

Germany, on the other hand, does have expressed plans to launch cannabis trials eventually, and when that happens the size and scope of the cannabis trials will likely be much larger than what is currently found elsewhere on the European continent, albeit on a timeline that is still unclear.